Ultragenyx Pharmaceutical | Les Charges D'Exploitation



Operating Expenses Changement Date
Acadia Pharmaceuticals USD 106.1M 112.66M 2024-12
Agios Pharmaceuticals USD 135.77M 1.11B 2024-12
Alnylam Pharmaceuticals USD 698.32M 120.5M 2024-12
BioMarin Pharmaceutical USD 585.91M 45.94M 2024-12
Insmed USD 334.86M 28M 2024-12
Ionis Pharmaceuticals USD 337.4M 54.93M 2024-12
Kyowa Hakko Kirin JPY 102.9B 107M 2024-09
MacroGenics USD 35.94M 20.58M 2024-12
Moderna USD 2.21B 280M 2024-12
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
PTC Therapeutics USD 275.66M 24.36M 2024-12
Regeneron Pharmaceuticals USD 2.8B 26.53B 2024-12
Sarepta Therapeutics USD 496.73M 51.76M 2024-12
Ultragenyx Pharmaceutical USD 287.15M 15.67M 2024-12
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12



Ultragenyx Pharmaceutical Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.